Home
       
 

Approach Martinsried

Fördergesellschaft IZB mbH
Am Klopferspitz 19
82152 Planegg/Martinsried

Fon: +49 (0) 89 - 700 656 70
Fax: +49 (0) 89 - 700 656 77
Email: info@izb-online.de

The way to IZB

Motorway / Autobahn A8
At crossing Mü.-West turn right and take direction Lindau/Garmisch-P./Mü.-Lochhausen (A99) - At Crossing Mü. Süd-West turn left and follow Garmisch-P./Mü.-Sendling/Mü.-Zentrum (A96)- Take Exit Mü.-Blumenau and turn right into Waldwiesenstraße direction Mü.-Blumenau/Mü.-Großhadern - after 900 m turn right into Würmtalstraße direction Planegg-Martinsried - after 1,6 km turn left into Am Klopferspitz - after 500 m visitor parking area on the left hand

Motorway / Autobahn A96
Take Exit Mü.-Blumenau and turn right into Waldwiesenstraße direction Mü.-Blumenau/Mü.-Großhadern - after 900 m turn right into Würmtalstraße direction Planegg-Martinsried - after 1,6 km turn left into Am Klopferspitz - after 500 m visitor parking area on the left hand

Motorway / Autobahn A9
At Crossing Neufahrn follow the signs on the right hand direction Mü.-West (A92) - Continue A92 direction Stuttgart/Mü.-West - At crossing Mü.-Allach follow the left sins direction Mü.-West/Lindau (A99) - At Crossing Mü. Süd-West turn left and follow Garmisch-P./Mü.- Sendling/Mü.-Zentrum (A96)- Take Exit Mü.-Blumenau and turn right into Waldwiesenstraße direction Mü.- Blumenau/Mü.-Großhadern - after 900 m turn right into Würmtalstraße direction Planegg-Martinsried - after 1,6 km turn left into Am Klopferspitz - after 500 m visitor parking area on the left hand

By train
ICE, IC or EC. Hourly trains to Munich Main Station (Hauptbahnhof). With every "S-Bahn" (regional train) in the direction Marienplatz / Ostbahnhof travel 2 stops to Marienplatz, change to the "U-Bahn" (subway) line 6 as far as "Klinikum Großhardern", change to the Bus number 266 and travel to the stop "IZB" not longer "Max-Planck-Institut". Overview Munich city transport system.pdf

By plane
From Munich airport "Franz Joseph Strauß" with the "S-Bahn" line 8 or 1 as far as Marienplatz. From there follow the instructions above for arriving by train.

 

 
       

print site

 

 

 
 
One of IZB
 
     
 
press releases
 
     
 
4SC to host conference call on 14 May 2013 to present first quarter results of 2013
10.05.2013
 
     
 
Evotec extends drug discovery alliance with Genentech
22.04.2013
 
     
 
ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells
18.04.2013
 
     
 
4SC to present at two upcoming investor conferences
12.04.2013
 
     
 
Analysis of complex protein-protein-interactions made easy: ChromoTek’s fluorescent two hybrid (F2H®) technology enables screening and validation of compounds in living cells
04.04.2013
 
     
 
Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress
26.03.2013
 
     
 
4SC AG announces financial results for a successful year 2012
25.03.2013
 
     
 
4SC to host conference cann and webcast on 25 March 2013 to present full year financial results for 2012
18.03.2013
 
     
 
ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition
11.03.2013
 
     
 
Biomolecular movies: Chromotek introduces Chromobody® plasmids for real time monitoring of key intracellular target molecules in vivo
11.03.2013
 
     
 
4SC AG: Dr. Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner
06.03.2013
 
     
 
4SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases
26.02.2013
 
     
 
4SC Discovery and BioNTech launch strategic cancer therapy research partnership
20.02.2013
 
     
 
LGC Standards announces distribution partnership with Biontex
15.01.2013
 
     
 
Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.
11.01.2013
 
     
 
Evotec and Yale University form Open Innovation Alliance
09.01.2013
 
     
 
4SC obtains key patent for anti-cancer compound resminostat in Europe
08.01.2013
 
     
 
Evotec expands collaboration with MedImmune, receives milestone payment
07.01.2013
 
     
 
Evotec acquires Cell Culture Service GmbH
03.01.2013
 
     
 
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
02.01.2013
 
     
 
ibidi is a Finalist in the 2012/13 German Economy Innovation Award Competition
19.12.2012
 
     
 
Evotec announces NMDA antagonist license agreement
17.12.2012
 
     
 
SuppreMol’s SM101 shows a sustained clinical activity and a favorable safety profile in Primary Immune Thrombocytopenia (ITP) patients
10.12.2012
 
     
 
4SC reports positive data from clinical Phase I trial with 4SC-205 in cancer patients and initiates study amendment to further investigate the compound based on new preclinical and clinical findings
05.12.2012
 
     
 
Evotec enters biology collaboration with Probiodrug
Hamburg, Germany – 28 November 2012: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innova...
28.11.2012
 
     
 
Evotec Receives CIR (French Research Tax Credit) Accreditation
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX) today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.
23.11.2012
 
     
  archive >>>